Related Experiment Video
Updated: Nov 25, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Children's Interstitial and Diffuse Lung Diseases (ChILD) in 2020.
Valentina Agnese Ferraro1, Stefania Zanconato1, Andrea Zamunaro1
1Pediatric Respiratory Medicine and Allergy Unit, Women's and Children's Health Department, University of Padova, via Giustiniani 2, 35128 Padova, Italy.
Children's interstitial lung diseases (chILD) are rare, diverse lung conditions in young children. Early diagnosis using imaging and genetic tests is crucial for timely treatment with anti-inflammatory drugs.
Area of Science:
- Pediatric Pulmonology
- Rare Diseases
- Respiratory Medicine
Background:
- Children's interstitial lung diseases (chILD) encompass a rare, heterogeneous group of diffuse lung disorders affecting infants and young children.
- These conditions present with varied clinical manifestations, often including nonspecific respiratory symptoms like dyspnea, tachypnea, cough, wheezing, and exercise intolerance.
- Specific chILD entities in children under two years include developmental disorders, growth abnormalities, neuroendocrine cell hyperplasia of infancy, pulmonary interstitial glycogenosis, and surfactant protein disorders.
Purpose of the Study:
- To provide an overview of children's interstitial lung diseases (chILD).
- To highlight the diagnostic approaches and treatment strategies for chILD.
- To emphasize the importance of physician familiarity with chILD for prompt diagnosis and management.
Main Methods:
- Review of clinical manifestations, diagnostic tools, and treatment options for chILD.
- Emphasis on the role of high-resolution computed tomography (HRCT) and genetic testing in diagnosis.
- Inclusion of laryngotracheal-bronchoscopy and lung biopsy for uncertain cases.
Main Results:
- chILD presents with a wide spectrum of symptoms, from asymptomatic to severe onset, commonly involving nonspecific respiratory signs.
- High-resolution computed tomography (HRCT) and genetic testing are central to the diagnostic process.
- Current pharmacological treatments are largely empiric, utilizing anti-inflammatory and immunomodulatory agents such as corticosteroids, hydroxychloroquine, and azithromycin.
Conclusions:
- Pediatric pulmonologists require familiarity with chILD to ensure timely diagnosis and effective patient management.
- Despite their rarity, prompt recognition and appropriate treatment of chILD are essential for improving patient outcomes.
- The diagnostic pathway involves a combination of imaging, genetic analysis, and, when necessary, invasive procedures like bronchoscopy and biopsy.
Related Concept Videos
Pulmonary Cycle: Exhalation
Other Pulmonary Disorders
Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-I: Introduction

